UCLA Health’s Outpatient Theranostics Center allows clinicians to treat up to 16 patients per day with Pluvicto and other ...

or advanced systemic therapy for prostate cancer. Data analysis included 182 patients who had a median pre-scan PSA level of 2.6 ng/mL Overall, 84% of the patients had positive PSMA-PET/CT results ...

is emerging as a prominent leader in adopting advanced prostate cancer treatments and diagnostics, including ...

M1 disease detected with PSMA-PET in 46 percent of patients with high-risk, nonmetastatic hormone-sensitive prostate cancer.

The FDA granted fast track designation to 64Cu-SAR-bisPSMA for PET imaging of PSMA-positive prostate cancer lesions in ...

PSMA-PET leverages ‘radiotracers’ that bind to prostate cancer cells, making them visible on PET scans and providing functional imaging that reveals the biological activity of cancer.

PSMA-PET imaging uses tiny amounts of radioactive "tracers," called radiotracers, that binds to prostate cancer cells, making them visible on PET scans. Unlike conventional imaging, which provides ...

These services include specialized options tailored to various cancer types. The PSMA PET CT scan is designed for prostate ...

PSMA-PET imaging uses tiny amounts of radioactive "tracers," called radiotracers, that binds to prostate cancer cells, making them visible on PET scans. Unlike conventional imaging, which provides ...

PSMA-PET/CT findings were positive in 84% of the patients. PSMA-PET/CT detected distant metastatic disease in 46% of patients, including 34% of patients after RP, 56% after definitive RT, and 60% ...

PSMA-PET imaging uses tiny amounts of radioactive “tracers,” called radiotracers, that binds to prostate cancer cells, making them visible on PET scans. Unlike conventional imaging, which provides ...